Project Grant R41AI184248
Award Date 9/26/25
Completion Date 8/31/26
Dollars Obligated $305K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
- This Project Grant award of $306,500 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a novel immunotherapeutic product, Agent-797, composed of invariant natural killer T (iNKT) cells. The project, led by Mink Therapeutics Inc., aims to evaluate the efficacy of Agent-797 in reducing graft-versus-host disease and improving immune engraftment in hematopoietic stem cell transplantation. The research...
- This $420,771 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a targeted genetic approach for treating Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a type of primary immune deficiency disorder. The research aims to restore immune function through chromosomal site-directed correction of the endogenous Artemis gene in hematopoietic stem cells. This builds on...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This federal Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program supports research conducted by Versiti Wisconsin, Inc. to study the regulation of recirculating and tissue-resident memory CD8+ T cells in homeostasis and inflammation. The research aims to elucidate how cytokines maintain these memory T cell populations, with implications for expanding memory CD8+ T...
- This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel chimeric antigen receptor (CAR) T-cell therapies to selectively target the PD-1+ HIV/SIV reservoir. The $862,398 award will fund research by the Fred Hutchinson Cancer Center to engineer CAR T-cell modalities that can be controlled by small molecule inhibitors or integrated into a link CAR...
- This $127,866 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the mobilization of hematopoietic stem/progenitor cells (HSPCs) from the bone marrow microenvironment in response to inflammation. The primary objective is to use a 3D human bone marrow microphysiological system (BM MPS) to study how extracellular vesicles derived from inflamed cells...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- The federal Project Grant award of $431,147 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate the mechanisms that drive infusion reactions (IRs) associated with monoclonal antibody (mAb) therapies. The research aims to better understand the systemic cytokine release that occurs during these IR events, with the goal of developing new approaches to prevent or mitigate...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Optimeos Life Sciences, Inc., a biotechnology company in Princeton, New Jersey. The grant will support the development of an "off-the-shelf" nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies, with an initial focus on adenosine deaminase severe combined immunodeficiency...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to further develop a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The key objectives are to design, fabricate, characterize, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant...